Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024

Fineline Cube Apr 11, 2024

Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...

Company Deals

STRATA Skin Sciences Renews Exclusive Distribution Deals in China and Japan

Fineline Cube Apr 11, 2024

STRATA Skin Sciences Inc. (NASDAQ: SSKN), a U.S.-based dermatology and plastic surgery firm, has announced...

Company Medical Device

Aptar Pharma Secures NMPA Approval for Airless Drug Delivery System in Chin

Fineline Cube Apr 11, 2024

Aptar Pharma, a U.S.-based company, announced that its Mezzo+ CS (China Support) Airless dispensing solution...

Company Policy / Regulatory

BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec

Fineline Cube Apr 11, 2024

Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...

Company Drug Medical Device

Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu

Fineline Cube Apr 11, 2024

Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...

Company Drug

Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults

Fineline Cube Apr 11, 2024

Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory...

Company

Boehringer Ingelheim’s Shanghai Unit Secures EMA and FDA Approval for Biopharmaceutical Supply

Fineline Cube Apr 11, 2024

Germany-based Boehringer Ingelheim has announced that its Shanghai-based Contract Manufacturing Organization (CMO), Boehringer Ingelheim Biopharmaceuticals...

Company Deals

Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation

Fineline Cube Apr 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics...

Company Deals

Genesis MedTech Secures Hundreds of Millions in Funding to Boost R&D and Manufacturing in China

Fineline Cube Apr 11, 2024

Singapore-based medical device company Genesis MedTech has raised “hundreds of millions” of renminbi in a...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors

Fineline Cube Apr 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...

Company

Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...

Company Deals

Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology

Fineline Cube Apr 10, 2024

Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition...

Company Deals

Bayer Partners with Google Cloud to Develop AI-Powered Medical Imaging Solutions

Fineline Cube Apr 10, 2024

Germany’s pharmaceutical and life sciences giant Bayer (ETR: BAYN) has joined forces with US technology...

Company Drug

Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma

Fineline Cube Apr 10, 2024

Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific...

Company Drug

Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for...

Company Drug

Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer

Fineline Cube Apr 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Pipeline with NMPA Approvals for Three Drugs

Fineline Cube Apr 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical trial approvals from China’s National...

Company Deals

Apeloa Pharmaceutical Partners with Heze Pharmaceutical for Semaglutide Biosimilar Development

Fineline Cube Apr 10, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a prominent player in the Chinese pharmaceutical industry, has...

Company Deals

Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline

Fineline Cube Apr 10, 2024

Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the...

Company Deals

Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China

Fineline Cube Apr 10, 2024

US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round,...

Posts pagination

1 … 331 332 333 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.